中华医学会肿瘤学分会肿瘤支持康复治疗学组. Clinical practice guidelines for cancer-related fatigue in China (2021 edition)[J]. China Oncology, 2021, 31(9): 852-872. DOI: 10.19401/j.cnki.1007-3639.2021.09.012.
Clinical practice guidelines for cancer-related fatigue in China (2021 edition)
Cancer has become one of the most important public issues which seriously influence the health condition of Chinese population. The cancer-related fatigue has drawn great attention. Studies have reported that cancer-related fatigue is the most common concomitant symptom of cancer. Cancer-related fatigue could negatively affect the work
social relationship
emotions
daily activities and quality of life of cancer patients
leading to discontinuation of the treatment and even influencing the time of survival in cancer patients. However
there is no relevant guideline to instruct the clinical diagnosis and treatment of cancer-related fatigue in China. Experts and scholars from the Tumor Support and Rehabilitation Therapy Group
the Oncology Committee of Chinese Medical Association summarized the research progress of cancer-related fatigue so as to transmit important information and guide clinical practice timely. This guideline mainly covers the definition
epidemiology
clinical manifestations
pathogenesis
interfering factors
types of Traditional Chinese Medicine syndrome
screening
clinical evaluation and integrative Traditional Chinese Medicine and Western medicine treatment
aiming to provide suggestions for the clinical diagnosis and treatment of cancer-related fatigue
to facilitate the promotion of standardized treatment for patients with cancer-related fatigue
and to improve the clinical prognosis of patients with cancer-related fatigue.
Guidelines for breast cancer diagnosis and treatment by China Anti-Cancer Association (2026 edition)
Interpretation of the 2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer: precision treatment guided by genotyping
China Anti-Cancer Association guideline for diagnosis and treatment of neuroendocrine neoplasms (2025 edition)
Practice guideline for the histopathological diagnosis of mesothelioma (2025 version)
Expert consensus of 177Lu-labeled PSMA radioligand therapy for clinical practice of prostate cancer (2024 edition)
Related Author
The Society of Breast Cancer China Anti-Cancer Association
Breast Oncology Group of the Oncology Branch of the Chinese Medical Association
Hao WANG
Jun LIANG
of Neuroendocrine Neoplasm of China Anti-Cancer Association Society
Expert Committee on Pathology of Chinese Research Hospital Association
Professional Committee on Tumor Pathology of Shanghai Anticancer Association
Nuclear Medicine Committee of China Anti-Cancer Association Cancer
Related Institution
Department of Radiotherapy, Qingdao Hospital, University of Health and Rehabilitation Science (Qingdao Municipal Hospital)
Oncology Medical Center, Peking University International Hospital